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Abstract
Phosphodiesterase III inhibitors combine positive inotropic and
vasodilator properties. These inhibitors are therefore frequently
used to treat low cardiac output and/or severe left heart failure
associated with cardiac surgery. Their effects on energy meta-
bolism and visceral organ function are not well studied, however,
particularly in comparison with their ‘competitors’ in daily practice
(that is, catecholamines).
In the previous issue of Critical Care, Heringlake and
colleagues compared the metabolic and renal effects of
adrenaline and the phosphodiesterase III inhibitor milrinone in
patients with low cardiac output after coronary artery bypass
surgery [1]. Demographic data of the study population, the
cardiopulmonary bypass time and baseline hemodynamics
were well matched. Adrenaline or milrinone were randomly
administered to achieve a cardiac index >3 l/min/m2 and were
maintained thereafter for the 14-hour study period. Patients
without the need for inotropic support served as controls.
Despite comparable hemodynamics, blood lactate, pyruvate,
and glucose concentrations were higher in the adrenaline-
treated patients, the latter being affiliated with higher
exogenous insulin requirements. This metabolic pattern was
accompanied with transitory higher lactate/pyruvate ratios,
indicative of a less balanced cytosolic redox status [2].
In the context of the landmark studies on intensive insulin use
by the group of Van den Berghe and colleagues, particularly
in patients undergoing cardiac surgery [3], the metabolic
effects of catecholamines and alternative drugs may assume
particular importance. It is well established that, similar to
other shock states, cardiogenic shock is characterised by a
hypermetabolic condition with insulin resistance, hyper-
lactatemia and increased oxygen demand that coincide with
both compromised tissue microcirculatory perfusion and
mitochondrial dysfunction [4,5].
In contrast to catecholamines, the metabolic effects of
phosphodiesterase III inhibitors have been poorly studied.
Phosphodiesterase III inhibitors (that is, enoximone, milrinone
and olprinone) have both vasodilatory and inotropic
properties, and have been shown to effectively increase the
cardiac index in patients with cardiogenic shock of various
etiologies [6,7]. In patients with hyperdynamic septic shock,
enoximone was associated with enhanced energy expen-
diture and oxygen consumption but significantly reduced the
rate of hepatic gluconeogenesis, while plasma lactate and
glucose concentrations and the lactate turnover rate did not
change [8]. This finding is of particular interest since gluco-
neogenesis is a highly oxygen-demanding pathway accoun-
ting for 50% of hepatic oxygen consumption [9] and is
inversely related to the protein synthesising capacity of the
liver [10].
In line with these observations, plasma lactate and glucose
levels did not change in the milrinone-treated patients in the
present study, possibly suggesting a more balanced hepato-
splanchnic oxygen demand and supply. In fact, perioperative
milrinone had antiinflammatory properties and improved
splanchnic perfusion in patients undergoing coronary artery
bypass grafting [11], and in patients with septic shock
enoximone but not dobutamine increased hepatosplanchnic
oxygen uptake concomitant with improved metabolic capacity
and a decreased hepatic tumor necrosis factor alpha release
[12]. Data for whole body oxygen consumption, carbon
dioxide production and cytokine release are lacking in the
present study, so the mechanism of the milrinone-related
improvement of the patients’ metabolic status remains
unresolved. It should be noted in this context that the glucose
control was handled fairly liberally at least in the adrenaline
group, since glycemia levels up to 240 mg/dl were tolerated.
A tighter glucose control in this group would consequently
probably have requested even higher insulin doses, which in
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turn might have also influenced the patients’ hemodynamic
status: in patients with chronic left heart failure undergoing a
euglycemic hyperinsulinemic clamp, insulin increased the
cardiac output as a result of moderate peripheral vasodilation,
while superior mesenteric flow remained unaffected [13].
In their present study, Heringlake and colleagues did not find
any significant effect of milrinone on standard parameters of
renal function (that is, creatinine clearance and fractional
sodium excretion). In contrast, blood cystatin-c levels and the
urinary α1-microglobulin concentrations – parameters that are
referred to closely mirror impaired glomerular filtration and
tubular injury, respectively [14] – showed more pronounced
impairment in the adrenaline-treated patients than in the
milrinone and control groups. The mechanism of this putative
renal protective property of milrinone remains unsettled in the
present study. One might speculate that phosphodiesterase
III inhibition increased juxtaglomerular cAMP concentrations,
thus causing increased renin secretion and a consecutively
higher renal perfusion pressure [15]. In addition, the less
strict glucose control in the adrenaline group might also be
responsible for the authors’ observation: even transient
hyperglycemia enhances formation of reactive oxygen
species [16], which in turn was shown to damage human
proximal tubular epithelial cells [17].
In summary, a number of studies are now available showing
that, during shock states, phosphodiesterase III inhibitors may
exert less ‘metabolic stress’ than the more potent
catecholamines adrenaline and noradrenaline It is well
established that catecholamines may cause hyperlactatemia
and hyperglycemia, the degree of which is directly related to
their specific β-receptor activity [18]. Given the
hyperglycemia-related aggravation of oxidative stress,
phosphodiesterase III inhibitors might prove an attractive
alternative and/or adjunct to the use of catecholamines in
patients with low cardiac output.
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